110 related articles for article (PubMed ID: 15918333)
1. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients.
Laguno M; Milinkovic A; de Lazzari E; Murillas J; Martínez E; Blanco JL; Loncá M; Biglia A; Leon A; García M; Larrousse M; García F; Miró JM; Gatell JM; Mallolas J
Antivir Ther; 2005; 10(3):423-9. PubMed ID: 15918333
[TBL] [Abstract][Full Text] [Related]
2. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin.
Moreno A; Quereda C; Moreno L; Perez-Elías MJ; Muriel A; Casado JL; Antela A; Dronda F; Navas E; Bárcena R; Moreno S
Antivir Ther; 2004 Feb; 9(1):133-8. PubMed ID: 15040545
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy.
Reiberger T; Kosi L; Maresch J; Breitenecker F; Payer BA; Wrba F; Rieger A; Gangl A; Peck-Radosavljevic M
J Infect Dis; 2010 Jul; 202(1):156-60. PubMed ID: 20486858
[TBL] [Abstract][Full Text] [Related]
4. Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors.
Bani-Sadr F; Lapidus N; Melchior JC; Ravaux I; Bensalem M; Rosa I; Cacoub P; Pol S; Perronne C; Carrat F
J Viral Hepat; 2008 Apr; 15(4):255-60. PubMed ID: 18307589
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy.
Bani-Sadr F; Carrat F; Pol S; Hor R; Rosenthal E; Goujard C; Morand P; Lunel-Fabiani F; Salmon-Ceron D; Piroth L; Pialoux G; Bentata M; Cacoub P; Perronne C;
J Acquir Immune Defic Syndr; 2005 Sep; 40(1):47-52. PubMed ID: 16123681
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
Ballesteros AL; Miró O; López S; Fuster D; Videla S; Martínez E; Garrabou G; Salas A; Côté H; Tor J; Rey-Joly C; Planas R; Clotet B; Tural C
Antivir Ther; 2004 Dec; 9(6):969-77. PubMed ID: 15651755
[TBL] [Abstract][Full Text] [Related]
7. Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.
Bräu N
J Antimicrob Chemother; 2005 Dec; 56(6):991-5. PubMed ID: 16308419
[TBL] [Abstract][Full Text] [Related]
8. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.
Loko MA; Bani-Sadr F; Winnock M; Lacombe K; Carrieri P; Neau D; Morlat P; Serfaty L; Dabis F; Salmon D;
J Viral Hepat; 2011 Jul; 18(7):e307-14. PubMed ID: 21692942
[TBL] [Abstract][Full Text] [Related]
9. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection.
Lafeuillade A; Hittinger G; Chadapaud S
Lancet; 2001 Jan; 357(9252):280-1. PubMed ID: 11214134
[TBL] [Abstract][Full Text] [Related]
10. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic issues in HIV/HCV-coinfected patients.
Sulkowski MS; Benhamou Y
J Viral Hepat; 2007 Jun; 14(6):371-86. PubMed ID: 17501757
[TBL] [Abstract][Full Text] [Related]
12. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
Soriano V; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de los Santos I; San Joaquín I; Echeverria S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola J; Blanco F; Martin-Carbonero L; García-Samaniego J; Nuñez M;
Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapy.
Lo Re V; Kostman JR; Gross R; Reddy KR; Mounzer K; Zemel BS; Rennert H; Stieritz DD; Putt M; Frank I; Strom BL
J Acquir Immune Defic Syndr; 2007 Mar; 44(3):344-50. PubMed ID: 17179767
[TBL] [Abstract][Full Text] [Related]
14. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy.
Butt AA
AIDS Read; 2003 Jul; 13(7):344-8. PubMed ID: 12889452
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hepatitis C in HIV-infected patients: regularly reassess the benefits and risks.
Prescrire Int; 2005 Dec; 14(80):226-9. PubMed ID: 16400748
[TBL] [Abstract][Full Text] [Related]
17. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
Mira JA; López-Cortés LF; Merino D; Arizcorreta-Yarza A; Rivero A; Collado A; Ríos-Villegas MJ; González-Serrano M; Torres-Tortoso M; Macías J; Valera-Bestard B; Fernández-Fuertes E; Girón-González JA; Lozano F; Pineda JA;
Antivir Ther; 2007; 12(8):1225-35. PubMed ID: 18240862
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up].
Seydi M; Morlat P; Bonnet F; Rambeloarisoa J; Bernard N; Lacoste D; Bonarek M; Trimoulet P; Ramanampamonjy R; Lafon ME; Dramé M; Beylot J
Rev Med Interne; 2005 Apr; 26(4):280-7. PubMed ID: 15820563
[TBL] [Abstract][Full Text] [Related]
19. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
Núñez M; Ocampo A; Aguirrebengoa K; Cervantes M; Pascual A; Echeverria S; Asensi V; Barreiro P; Garcia-Samaniego J; Soriano V;
J Viral Hepat; 2008 May; 15(5):363-9. PubMed ID: 18179454
[TBL] [Abstract][Full Text] [Related]
20. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.
Voigt E; Schulz C; Klausen G; Goelz J; Mauss S; Schmutz G; Jessen H; Weitner L; Mutz A; Schranz D; Rockstroh JK;
J Infect; 2006 Jul; 53(1):36-42. PubMed ID: 16269184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
